Free tool
FAERS Monitor: Pancreaze
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022523 or its brand name (Pancreaze, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.
Reports
678
Serious
365
54% of reports
Hospitalization
212
Death reported
49
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea63
- drug dose omission36
- death29
- abdominal pain upper28
- infective pulmonary exacerbation of cystic fibrosis27
- nausea27
- pneumonia27
- pain25
- cystic fibrosis23
- drug ineffective23
- vomiting22
- abdominal pain20
- fatigue20
- malaise20
- headache19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 16 |
| 2011 | 45 |
| 2012 | 33 |
| 2013 | 12 |
| 2014 | 10 |
| 2015 | 83 |
| 2016 | 57 |
| 2017 | 53 |
| 2018 | 45 |
| 2019 | 38 |
| 2020 | 69 |
| 2021 | 45 |
| 2022 | 33 |
| 2023 | 40 |
| 2024 | 44 |
| 2025 | 29 |
| 2026 | 26 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,481 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 27 | 154.7 | 106.8 | 3,951 |
| cystic fibrosisSignal | 23 | 129.4 | 86.5 | 2,793 |
| drug dose omissionSignal | 36 | 6.8 | 4.9 | 172 |
| abdominal pain upperSignal | 28 | 4.2 | 2.9 | 66 |
| diarrhoeaSignal | 63 | 3.0 | 2.4 | 86 |
| abdominal painSignal | 20 | 2.7 | 1.7 | 19 |
| pneumoniaSignal | 27 | 2.6 | 1.8 | 25 |
| vomiting | 22 | 1.5 | 1.0 | 3 |
| malaise | 20 | 1.4 | 0.9 | 2 |
| pain | 25 | 1.3 | 0.9 | 1 |
| nausea | 27 | 1.1 | 0.7 | 0 |
| death | 29 | 1.0 | 0.7 | 0 |
| headache | 19 | 0.9 | 0.6 | 0 |
| fatigue | 20 | 0.8 | 0.5 | 1 |
| drug ineffective | 23 | 0.5 | 0.4 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.